Oxyntomodulin vs Glucagon

Both are cut from the same precursor, proglucagon. Glucagon acts mainly at the glucagon receptor to raise blood glucose; oxyntomodulin contains the glucagon sequence plus an extension and also activates the GLP-1 receptor.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Oxyntomodulin

A natural 37-amino-acid gut hormone that activates both the GLP-1 and glucagon receptors — the template for the dual-agonist drug class.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

Glucagon

The pancreatic alpha-cell hormone that raises blood glucose — the counter-regulatory partner to insulin and a component of newer multi-agonist research molecules.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Oxyntomodulin	Glucagon
The key difference	Dual GLP-1/glucagon activity	Glucagon receptor only
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Released from intestinal L-cells after meals, oxyntomodulin combines GLP-1-receptor effects (satiety, insulin) with glucagon-receptor effects (energy expenditure).	Glucagon binds the glucagon receptor (GCGR), mainly on liver cells, driving glycogen breakdown and glucose production.
Status	Endogenous hormone and research tool; oxyntomodulin-based analogues are in late-stage development.	An approved medicine for severe hypoglycaemia, available as injectable, nasal and ready-to-use aqueous analogue (dasiglucagon) forms; glucagon-receptor antagonists have also been explored.
Reported safety signals	As a short-lived native hormone, research administration has been brief; class effects follow GLP-1/glucagon biology.	Trials report safety and tolerability for rescue formulations comparable to reconstituted glucagon injection; glucagon-receptor blockade has brought its own adverse effects in research.
A key study	Reviews oxyntomodulin as a dual GLP-1R/GCGR agonist with weight-lowering effects. (Mol Metab 2014, PMID 24749050)	In a phase 3 randomised trial in adults with type 1 diabetes, median time to glucose recovery was 10 minutes with dasiglucagon versus 40 minutes with placebo. (Diabetes Care 2021, PMID 35239971)

WHEN TO RESEARCH WHICH

Glucagon for counter-regulation and hypoglycaemia; oxyntomodulin for combined satiety and energy-expenditure research. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Oxyntomodulin] Action and therapeutic potential of oxyntomodulin — Mol Metab 2014. PMID 24749050
[Oxyntomodulin] Unraveling oxyntomodulin, GLP1’s enigmatic brother — J Endocrinol 2012. PMID 23019069
[Oxyntomodulin] Oxyntomodulin - past, present and future — Peptides 2025. PMID 40187415
[Glucagon] Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial — Diabetes Care 2021. PMID 35239971
[Glucagon] Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis — Acta Diabetol 2020. PMID 32025860
[Glucagon] Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis — Diabetes Care 2025. PMID 40834249

FREQUENTLY ASKED

What is the difference between Oxyntomodulin and Glucagon?

What is the regulatory status of Oxyntomodulin and Glucagon?

Oxyntomodulin: Endogenous hormone and research tool; oxyntomodulin-based analogues are in late-stage development. Glucagon: An approved medicine for severe hypoglycaemia, available as injectable, nasal and ready-to-use aqueous analogue (dasiglucagon) forms; glucagon-receptor antagonists have also been explored.

What safety signals have been reported?

Oxyntomodulin: As a short-lived native hormone, research administration has been brief; class effects follow GLP-1/glucagon biology. Glucagon: Trials report safety and tolerability for rescue formulations comparable to reconstituted glucagon injection; glucagon-receptor blockade has brought its own adverse effects in research.

Which studies is this comparison based on?

For Oxyntomodulin: “Action and therapeutic potential of oxyntomodulin” (PMID 24749050); “Unraveling oxyntomodulin, GLP1’s enigmatic brother” (PMID 23019069); “Oxyntomodulin - past, present and future” (PMID 40187415). For Glucagon: “Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial” (PMID 35239971); “Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis” (PMID 32025860); “Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis” (PMID 40834249).